Vitality Watch

Dossier rss preclinical 23-sep-2026
Animal model, organoid, or cell-culture result — not yet human

Therapeutic Immune Reprogramming by Rapamycin Attenuates Plaque Inflammation and Lymphoid Immune Responses in Aged Atherosclerotic Mice

Key claim: Rapamycin therapeutically reprograms immune responses to attenuate atherosclerotic plaque inflammation and lymphoid immune activity in aged mice.

Abstract

Aging Cell, Volume 25, Issue 10, October 2026.

Why this matters

Rapamycin’s aging-mechanism narrative has centered on cellular growth control, autophagy, and senescence; this study operationalizes a distinct arm — therapeutic reprogramming of aged adaptive immunity at the atherosclerotic plaque — inside a disease-relevant aged model. It extends the mTOR-inhibition-as-geroprotection story into cardiovascular immunopathology but keeps the evidence squarely preclinical, without translating the immune-reprogramming claim to human plaque or cardiovascular event endpoints.

Source

Link

Briefing card

Therapeutic Immune Reprogramming by Rapamycin Attenuates Plaque Inflammation and Lymphoid Immune Responses in Aged Atherosclerotic Mice
Stage: preclinical · rss · 23-sep-2026

If you're following rapamycin's cardiovascular rationale, this adds aged-mouse mechanistic support for plaque-inflammation effects — not human outcome data.

Rapamycin therapeutically reprograms immune responses to attenuate atherosclerotic plaque inflammation and lymphoid immune activity in aged mice.

Cross-references (0)

None recorded — doctrine links and citations appear here as scans and citation sweeps find them.

External: url:https://onlinelibrary.wiley.com/doi/10.1111/acel.70730?af=R

build build 880 · 2bcef25 · 2026-11-18